John D. Powderly
About
John D. Powderly is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, John D. Powderly has authored 155 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 138 papers in Oncology, 44 papers in Immunology and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in John D. Powderly's work include Cancer Immunotherapy and Biomarkers (103 papers), CAR-T cell therapy research (44 papers) and Immunotherapy and Immune Responses (32 papers). John D. Powderly is often cited by papers focused on Cancer Immunotherapy and Biomarkers (103 papers), CAR-T cell therapy research (44 papers) and Immunotherapy and Immune Responses (32 papers). John D. Powderly collaborates with scholars based in United States, France and Spain. John D. Powderly's co-authors include Julie R. Brahmer, Suzanne L. Topalian, Charles G. Drake, William H. Sharfman, Drew M. Pardoll, Janis M. Taube, Alan J. Korman, Ira Wollner, Joel Picus and Robert A. Anders and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.
In The Last Decade
John D. Powderly
148 papers receiving 7.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| John D. Powderly United States | 37 | 6.5k | 3.5k | 2.2k | 1.4k | 665 | 155 | 7.9k | ||
| Shin Foong Ngiow United States | 31 | 4.8k 0.7× | 4.4k 1.2× | 922 0.4× | 1.3k 0.9× | 513 0.8× | 44 | 7.1k | ||
| Hossein Borghaei United States | 43 | 7.2k 1.1× | 1.9k 0.5× | 4.6k 2.1× | 1.4k 1.0× | 1.0k 1.5× | 258 | 9.0k | ||
| Helen K. Angell United Kingdom | 22 | 4.0k 0.6× | 2.7k 0.8× | 1.9k 0.9× | 2.1k 1.6× | 1.4k 2.1× | 40 | 6.5k | ||
| Florent Petitprez France | 23 | 3.7k 0.6× | 3.0k 0.8× | 2.2k 1.0× | 2.4k 1.8× | 1.6k 2.4× | 36 | 7.0k | ||
| Nicolás A. Giraldo France | 21 | 3.6k 0.5× | 2.4k 0.7× | 2.2k 1.0× | 2.0k 1.4× | 1.5k 2.2× | 33 | 6.1k | ||
| Melanie A. Leiby United States | 6 | 6.1k 0.9× | 1.5k 0.4× | 3.9k 1.8× | 795 0.6× | 930 1.4× | 7 | 7.2k | ||
| Tracee L. McMiller United States | 13 | 4.2k 0.7× | 2.6k 0.7× | 1.1k 0.5× | 841 0.6× | 384 0.6× | 26 | 5.1k | ||
| Joseph I. Clark United States | 37 | 3.8k 0.6× | 2.4k 0.7× | 3.1k 1.4× | 2.5k 1.8× | 1.0k 1.5× | 122 | 7.4k | ||
| Bartosz Chmielowski United States | 41 | 4.4k 0.7× | 1.8k 0.5× | 1.8k 0.8× | 2.6k 1.9× | 506 0.8× | 180 | 7.0k | ||
| Reshma Rangwala United States | 18 | 7.0k 1.1× | 1.8k 0.5× | 4.4k 2.0× | 1.4k 1.0× | 1.2k 1.7× | 41 | 9.2k |
Countries citing papers authored by John D. Powderly
Since
Specialization
Citations
This map shows the geographic impact of John D. Powderly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John D. Powderly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John D. Powderly more than expected).
Fields of papers citing papers by John D. Powderly
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by John D. Powderly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John D. Powderly. The network helps show where John D. Powderly may publish in the future.
Co-authorship network of co-authors of John D. Powderly
This figure shows the co-authorship network connecting the top 25 collaborators of John D. Powderly. A scholar is included among the top collaborators of John D. Powderly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John D. Powderly. John D. Powderly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Naing, Aung, Amit Mahipal, Milind Javle, et al.. (2025). Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. PubMed. 8(1). 71–81.
2.
Melero, Ignacio, Judy S. Wang, Martin Gutierrez, et al.. (2024). Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.. Journal of Clinical Oncology. 42(16_suppl). 2588–2588.
3.
Starodub, Alexander, Sung‐Bae Kim, Diwakar Davar, et al.. (2024). TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.. Journal of Clinical Oncology. 42(16_suppl). 2601–2601.
4.
Coward, Jermaine, Ganessan Kichenadasse, John Park, et al.. (2024). Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15010–e15010.
5.
Sharma, Manish, John H. Strickler, David Sommerhalder, et al.. (2024). First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.. Journal of Clinical Oncology. 42(16_suppl). 3515–3515.
6.
Yarchoan, Mark, John D. Powderly, Bruno R. Bastos, et al.. (2024). First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Research Communications. 4(4). 1100–1110.
7.
Babu, Sunil, Shunsuke Kondo, Alexander I. Spira, et al.. (2023). 1076TiP First-in-human study of ABBV-514 as monotherapy and in combination with budigalimab in patients with advanced solid tumors. Annals of Oncology. 34. S647–S648.
8.
Brahmer, Julie R., Charles G. Drake, Ira Wollner, et al.. (2023). Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. Journal of Clinical Oncology. 41(4). 715–723.
9.
Goldman, Jonathan W., Sarina A. Piha‐Paul, Brendan D. Curti, et al.. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(17). 3709–3719.
10.
Naing, Aung, John D. Powderly, John Nemunaitis, et al.. (2022). Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study. Journal for ImmunoTherapy of Cancer. 10(3). e004223–e004223.
11.
Petrylak, Daniel P., Yohann Loriot, David R. Shaffer, et al.. (2021). Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research. 27(12). 3360–3369.
12.
Shenderov, Eugene, Piotr J. Wysocki, Wen Xu, et al.. (2021). 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion. Annals of Oncology. 32. S657–S659.
13.
Demetri, George D., Jason J. Luke, Antoine Hollebecque, et al.. (2021). First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clinical Cancer Research. 27(13). 3556–3566.
14.
Glisson, Bonnie S., Rom S. Leidner, Robert L. Ferris, et al.. (2020). Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research. 26(20). 5358–5367.
15.
Hamid, Omid, Luciana Molinero, Christopher R. Bolen, et al.. (2019). Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. Clinical Cancer Research. 25(20). 6061–6072.
16.
Garassino, Marina Chiara, Byoung Chul Cho, Julien Mazières, et al.. (2018). P1.01-21 Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC. Journal of Thoracic Oncology. 13(10). S467–S468.
17.
Powderly, John D., Manish R. Patel, Jina Lee, et al.. (2017). CA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study. Annals of Oncology. 28. v405–v406.
18.
Garassino, Marina Chiara, Johan Vansteenkiste, Joo-Hang Kim, et al.. (2017). PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study. Journal of Thoracic Oncology. 12(1). S10–S11.
19.
Morse, Michael A., Robert Chapman, John D. Powderly, et al.. (2011). Phase I Study Utilizing a Novel Antigen-Presenting Cell–Targeted Vaccine with Toll-like Receptor Stimulation to Induce Immunity to Self-antigens in Cancer Patients. Clinical Cancer Research. 17(14). 4844–4853.
20.
Kuhns, Jennifer J., Susan E. Burkett, John D. Powderly, et al.. (2003). Host Absence of CCR5 Potentiates Dendritic Cell Vaccination. The Journal of Immunology. 170(8). 4201–4208.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shin Foong Ngiow Breakdown of academic impact, for papers by Hossein Borghaei Breakdown of academic impact, for papers by Helen K. Angell Breakdown of academic impact, for papers by Florent Petitprez Breakdown of academic impact, for papers by Nicolás A. Giraldo Breakdown of academic impact, for papers by Melanie A. Leiby Breakdown of academic impact, for papers by Tracee L. McMiller Breakdown of academic impact, for papers by Joseph I. Clark Breakdown of academic impact, for papers by Bartosz Chmielowski Breakdown of academic impact, for papers by Reshma Rangwala